The lack of transparency in the safety data of China’s vaccine producers, Sinopharm and Sinovac, which use an inactivated form of the virus, was highlighted in a British Medical Journal (BMJ) article in April. It stated that ‘no phase III trial data for any of the Chinese vaccine candidates have been published in a peer reviewed journal’.